Kurt Vermeire

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/7718603/publications.pdf

Version: 2024-02-01

71 papers	2,581 citations	201385 27 h-index	197535 49 g-index
90 all docs	90 docs citations	90 times ranked	2805 citing authors

#	Article	IF	Citations
1	AMD3100, a Potent and Specific Antagonist of the Stromal Cell-Derived Factor-1 Chemokine Receptor CXCR4, Inhibits Autoimmune Joint Inflammation in IFN-Î³ Receptor-Deficient Mice. Journal of Immunology, 2001, 167, 4686-4692.	0.4	245
2	Immunomodulatory Properties of Interferon-gamma: An Updatea. Annals of the New York Academy of Sciences, 1998, 856, 22-32.	1.8	168
3	Resistance Mutations in Human Immunodeficiency Virus Type 1 Integrase Selected with Elvitegravir Confer Reduced Susceptibility to a Wide Range of Integrase Inhibitors. Journal of Virology, 2008, 82, 10366-10374.	1.5	153
4	Mannose-Specific Plant Lectins from the Amaryllidaceae Family Qualify as Efficient Microbicides for Prevention of Human Immunodeficiency Virus Infection. Antimicrobial Agents and Chemotherapy, 2004, 48, 3858-3870.	1.4	147
5	Microvirin, a Novel Î±(1,2)-Mannose-specific Lectin Isolated from Microcystis aeruginosa, Has Anti-HIV-1 Activity Comparable with That of Cyanovirin-N but a Much Higher Safety Profile. Journal of Biological Chemistry, 2010, 285, 24845-24854.	1.6	108
6	Anti-IL-12 antibody prevents the development and progression of collagen-induced arthritis in IFN-Î³ receptor-deficient mice. European Journal of Immunology, 1998, 28, 2143-2151.	1.6	99
7	Profile of Resistance of Human Immunodeficiency Virus to Mannose-Specific Plant Lectins. Journal of Virology, 2004, 78, 10617-10627.	1.5	94
8	Pro-inflammatory properties of stromal cell-derived factor-1 (CXCL12) in collagen-induced arthritis. Arthritis Research and Therapy, 2005, 7, R1208.	1.6	91
9	Inhibition of Human Immunodeficiency Virus Replication by a Dual CCR5/CXCR4 Antagonist. Journal of Virology, 2004, 78, 12996-13006.	1.5	81
10	Carbohydrate-Binding Agents Efficiently Prevent Dendritic Cell-Specific Intercellular Adhesion Molecule-3-Grabbing Nonintegrin (DC-SIGN)-Directed HIV-1 Transmission to T Lymphocytes. Molecular Pharmacology, 2007, 71, 3-11.	1.0	80
11	CADA, a novel CD4-targeted HIV inhibitor, is synergistic with various anti-HIV drugs in vitro. Aids, 2004, 18, 2115-2125.	1.0	67
12	Safety concerns for the potential use of cyanovirin-N as a microbicidal anti-HIV agent. International Journal of Biochemistry and Cell Biology, 2008, 40, 2802-2814.	1.2	67
13	CADA Inhibits Human Immunodeficiency Virus and Human Herpesvirus 7 Replication by Down-modulation of the Cellular CD4 Receptor. Virology, 2002, 302, 342-353.	1.1	63
14	Evaluation of SDF-1/CXCR4-induced Ca2+ signaling by fluorometric imaging plate reader (FLIPR) and flow cytometry. Cytometry, 2003, 51A, 35-45.	1.8	63
15	The Anti-HIV Potency of Cyclotriazadisulfonamide Analogs Is Directly Correlated with Their Ability to Down-Modulate the CD4 Receptor. Molecular Pharmacology, 2003, 63, 203-210.	1.0	54
16	Sugar-Binding Proteins Potently Inhibit Dendritic Cell Human Immunodeficiency Virus Type 1 (HIV-1) Infection and Dendritic-Cell-Directed HIV-1 Transfer. Journal of Virology, 2005, 79, 13519-13527.	1.5	53
17	Mac-1+ myelopoiesis induced by CFA: a clue to the paradoxical effects of IFN-Î³ in autoimmune disease models. Trends in Immunology, 2001, 22, 367-371.	2.9	47
18	Establishment of a novel CCR5 and CXCR4 expressing CD4+ cell line which is highly sensitive to HIV and suitable for high-throughput evaluation of CCR5 and CXCR4 antagonists. Retrovirology, 2004, 1, 2.	0.9	44

#	Article	IF	Citations
19	Endothelial dysfunction in dengue virus pathology. Reviews in Medical Virology, 2015, 25, 50-67.	3.9	44
20	The candidate sulfonated microbicide, PRO 2000, has potential multiple mechanisms of action against HIV-1. Antiviral Research, 2009, 84, 38-47.	1.9	41
21	Resistance of HIV-1 to the broadly HIV-1-neutralizing, anti-carbohydrate antibody 2G12. Virology, 2007, 360, 294-304.	1.1	40
22	Signal Peptide-Binding Drug as a Selective Inhibitor of Co-Translational Protein Translocation. PLoS Biology, 2014, 12, e1002011.	2.6	39
23	Mutations at the CXCR4 interaction sites for AMD3100 influence anti-CXCR4 antibody binding and HIV-1 entry. FEBS Letters, 2003, 546, 300-306.	1.3	37
24	Fluorescent CXCL12AF647 as a novel probe for nonradioactive CXCL12/CXCR4 cellular interaction studies. Cytometry, 2004, 61A, 178-188.	1.8	36
25	Inhibitors of protein translocation across membranes of the secretory pathway: novel antimicrobial and anticancer agents. Cellular and Molecular Life Sciences, 2018, 75, 1541-1558.	2.4	35
26	Synthesis and Structureâ^'Activity Relationship Studies of CD4 Down-Modulating Cyclotriazadisulfonamide (CADA) Analogues. Journal of Medicinal Chemistry, 2006, 49, 1291-1312.	2.9	34
27	CXCR4-targeting nanobodies differentially inhibit CXCR4 function and HIV entry. Biochemical Pharmacology, 2018, 158, 402-412.	2.0	34
28	Immunosuppressive drugs in organ transplantation to prevent allograft rejection: Mode of action and side effects. Journal of Immunological Sciences, 2019, 3, 14-21.	0.5	27
29	Anti-HIV agents targeting the interaction of gp120 with the cellular CD4 receptor. Expert Opinion on Investigational Drugs, 2005, 14, 1199-1212.	1.9	26
30	Specific CD4 down-modulating compounds with potent anti-HIV activity. Journal of Leukocyte Biology, 2003, 74, 667-675.	1.5	22
31	Inhibitors of HIV Infection via the Cellular CD4 Receptor. Current Medicinal Chemistry, 2006, 13, 731-743.	1.2	22
32	Specific Targeting of the F13L Protein by St-246 Affects Orthopoxvirus Production Differently. Antiviral Therapy, 2008, 13, 977-990.	0.6	22
33	CD4 Down-Modulating Compounds with Potent Anti-HIV Activity. Current Pharmaceutical Design, 2004, 10, 1795-1803.	0.9	20
34	Chlorogenic Compounds from Coffee Beans Exert Activity against Respiratory Viruses. Planta Medica, 2017, 83, 615-623.	0.7	19
35	CADA, a Potential Anti-HIV Microbicide that Specifically Targets the Cellular CD4 Receptor. Current HIV Research, 2008, 6, 246-256.	0.2	18
36	Cyclotriazadisulfonamides: promising new CD4-targeted anti-HIV drugs. Journal of Antimicrobial Chemotherapy, 2005, 56, 270-272.	1.3	17

#	Article	IF	Citations
37	Synergistic in vitro anti-HIV type 1 activity of tenofovir with carbohydrate-binding agents (CBAs). Antiviral Research, 2011, 90, 200-204.	1.9	17
38	A Proteomic Survey Indicates Sortilin as a Secondary Substrate of the ER Translocation Inhibitor Cyclotriazadisulfonamide (CADA). Molecular and Cellular Proteomics, 2017, 16, 157-167.	2.5	17
39	Development and in vitro evaluation of chloroquine gels as microbicides against HIV-1 infection. Virology, 2008, 378, 306-310.	1.1	16
40	Unsymmetrical Cyclotriazadisulfonamide (CADA) Compounds as Human CD4 Receptor Down-Modulating Agents. Journal of Medicinal Chemistry, 2011, 54, 5712-5721.	2.9	16
41	Tuning Side Arm Electronics in Unsymmetrical Cyclotriazadisulfonamide (CADA) Endoplasmic Reticulum (ER) Translocation Inhibitors to Improve their Human Cluster of Differentiation 4 (CD4) Receptor Down-Modulating Potencies. Journal of Medicinal Chemistry, 2016, 59, 2633-2647.	2.9	16
42	Inhibitors of the Sec61 Complex and Novel High Throughput Screening Strategies to Target the Protein Translocation Pathway. International Journal of Molecular Sciences, 2021, 22, 12007.	1.8	16
43	Early identification of availability issues for poorly water-soluble microbicide candidates in biorelevant media: A case study with saquinavir. Antiviral Research, 2011, 91, 217-223.	1.9	14
44	Design and cellular kinetics of dansyl-labeled CADA derivatives with anti-HIV and CD4 receptor down-modulating activity. Biochemical Pharmacology, 2007, 74, 566-578.	2.0	13
45	Ribonuclease-neutralized pancreatic microsomal membranes from livestock for in vitro co-translational protein translocation. Analytical Biochemistry, 2015, 484, 102-104.	1.1	12
46	Preprotein signature for full susceptibility to the coâ€translational translocation inhibitor cyclotriazadisulfonamide. Traffic, 2020, 21, 250-264.	1.3	12
47	Labyrinthopeptin A1 inhibits dengue and Zika virus infection by interfering with the viral phospholipid membrane. Virology, 2021, 562, 74-86.	1.1	12
48	Modest Human Immunodeficiency Virus Coreceptor Function of CXCR3 Is Strongly Enhanced by Mimicking the CXCR4 Ligand Binding Pocket in the CXCR3 Receptor. Journal of Virology, 2007, 81, 3632-3639.	1.5	11
49	Complete Genome Sequence of a New Ebola Virus Strain Isolated during the 2017 Likati Outbreak in the Democratic Republic of the Congo. Microbiology Resource Announcements, 2019, 8, .	0.3	11
50	The Antiviral Activity of the CXCR4 Antagonist AMD3100 Is Independent of the Cytokine-Induced CXCR4/HIV Coreceptor Expression Level. AIDS Research and Human Retroviruses, 2003, 19, 1135-1139.	0.5	10
51	Human Immunodeficiency Virus Type 1 Escape from Cyclotriazadisulfonamide-Induced CD4-Targeted Entry Inhibition Is Associated with Increased Neutralizing Antibody Susceptibility. Journal of Virology, 2009, 83, 9577-9583.	1.5	10
52	A unique class of lignin derivatives displays broad anti-HIV activity by interacting with the viral envelope. Virus Research, 2019, 274, 197760.	1.1	10
53	A facile one pot multi component synthesis of alkyl 4-oxo-coumarinyl ethylidene hydrazono-thiazolidin-5-ylidene acetates and their antiviral activity. Journal of Molecular Structure, 2022, 1249, 131662.	1.8	10
54	SARS-CoV-2 Permissive glioblastoma cell line for high throughput antiviral screening. Antiviral Research, 2022, 203, 105342.	1.9	9

#	Article	IF	Citations
55	Accounting for population structure reveals ambiguity in the Zaire Ebolavirus reservoir dynamics. PLoS Neglected Tropical Diseases, 2020, 14, e0008117.	1.3	8
56	The CD4 Receptor: An Indispensable Protein in T Cell Activation and A Promising Target for Immunosuppression. Archives of Microbiology & Immunology, 2019, 03, .	0.1	8
57	Intracellular flow cytometry complements RT-qPCR detection of circulating SARS-CoV-2 variants of concern. BioTechniques, 2022, 72, 245-254.	0.8	8
58	Syntheses and anti-HIV and human cluster of differentiation 4 (CD4) down-modulating potencies of pyridine-fused cyclotriazadisulfonamide (CADA) compounds. Bioorganic and Medicinal Chemistry, 2020, 28, 115816.	1.4	7
59	A Proteomic Study on the Membrane Protein Fraction of T Cells Confirms High Substrate Selectivity for the ER Translocation Inhibitor Cyclotriazadisulfonamide. Molecular and Cellular Proteomics, 2021, 20, 100144.	2.5	7
60	Improving potencies and properties of CD4 down-modulating CADA analogs. Expert Opinion on Drug Discovery, 2012, 7, 39-48.	2.5	6
61	Metal complexes of pyridine-fused macrocyclic polyamines targeting the chemokine receptor CXCR4. Organic and Biomolecular Chemistry, 2015, 13, 10517-10526.	1.5	6
62	Use of a sequential high throughput screening assay to identify novel inhibitors of the eukaryotic SRP-Sec61 targeting/translocation pathway. PLoS ONE, 2018, 13, e0208641.	1.1	6
63	Advancing Marburg virus antiviral screening: Optimization of a novel T7 polymerase-independent minigenome system. Antiviral Research, 2021, 185, 104977.	1.9	6
64	Small Molecule Cyclotriazadisulfonamide Abrogates the Upregulation of the Human Receptors CD4 and 4-1BB and Suppresses In Vitro Activation and Proliferation of T Lymphocytes. Frontiers in Immunology, 2021, 12, 650731.	2.2	6
65	Reduced DNAJC3 Expression Affects Protein Translocation across the ER Membrane and Attenuates the Down-Modulating Effect of the Translocation Inhibitor Cyclotriazadisulfonamide. International Journal of Molecular Sciences, 2022, 23, 584.	1.8	6
66	Identification of novel Ebola virus inhibitors using biologically contained virus. Antiviral Research, 2022, 200, 105294.	1.9	5
67	Reduction of Progranulin-Induced Breast Cancer Stem Cell Propagation by Sortilin-Targeting Cyclotriazadisulfonamide (CADA) Compounds. Journal of Medicinal Chemistry, 2021, 64, 12865-12876.	2.9	4
68	Heterocyclic Chemistry, 2022, 59, 1604-1615.	1.4	3
69	PRO 2000, a broadly active anti-HIV sulfonated compound, inhibits viral entry by multiple mechanisms. Retrovirology, 2010, 7, .	0.9	1
70	Development of a T7-Independent MARV Minigenome System. Proceedings (mdpi), 2020, 50, .	0.2	0
71	Synthesis of Anti-HIV CADA Compounds and Quantitative Structure-Activity Relationships for CD4 Down-Modulation. , 2003, , 119.		0